WVE
VENTE TOTALE: 23 996 titres (~135 071,96 $ US)
- Insiders
- Wagner Heidi L, Rawcliffe Adrian, TAKANASHI KEN, Tan Aik Na
- Total bought
- —
- Total sold
- $135,072
- Last activity
- 2026-08-12
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-16
WVE presents a high-risk, speculative setup: strong liquidity (score 85) provides a short-term runway, but catastrophic fundamental trends (score 25, -478% net margin, negative OCF) signal no near-term path to…
The first sentence of the analysis written for WVE on 2026-08-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 79.3% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -478.3% | -89.6% | -51.4% | -4416.1% | -298.9% | |
| Ebitda Margin | -457.6% | -81.6% | -43.2% | -4138.9% | -274.9% | |
| Operating Profit Margin | -504.1% | -101.9% | -60.0% | -4459.3% | -310.1% | |
| Pretax Profit Margin | -478.3% | -89.6% | -51.4% | -4416.1% | -298.9% | |
| Continuous Operations Profit Margin | -478.3% | -89.6% | -50.8% | -4434.7% | -298.4% | |
| Net Profit Margin | -478.3% | -89.6% | -50.8% | -4434.7% | -298.4% | |
| Bottom Line Profit Margin | -478.3% | -89.6% | -50.8% | -4434.7% | -298.4% | |
| Current Ratio | 6.467 | 2.888 | 1.262 | 1.378 | 2.532 | |
| Quick Ratio | 6.467 | 2.888 | 1.262 | 1.378 | 2.532 | |
| Solvency Ratio | -1.742 | -0.619 | -0.205 | -0.792 | -0.644 | |
| Cash Ratio | 6.333 | 2.723 | 1.075 | 1.237 | 2.345 | |
| Price To Earnings Ratio | -14.050 | -17.671 | -9.352 | -3.415 | -1.331 | |
| Price To Earnings Growth Ratio | -0.193 | -0.596 | 0.127 | 0.260 | 0.035 | |
| Forward Price To Earnings Growth Ratio | -0.193 | -0.596 | 0.127 | 0.260 | 0.035 | |
| Price To Earnings Diluted Ratio | -14.050 | -17.671 | -9.352 | -3.415 | -1.331 | |
| Price To Earnings Diluted Growth Ratio | -0.193 | -0.596 | 0.127 | 0.260 | 0.035 | |
| Price To Book Ratio | 5.448 | 8.164 | 13.520 | -12.242 | 5.007 | |
| Price To Sales Ratio | 67.102 | 15.794 | 4.729 | 151.272 | 3.973 | |
| Price To Free Cash Flow Ratio | -15.291 | -11.256 | -26.078 | -4.274 | -1.817 | |
| Price To Operating Cash Flow Ratio | -15.291 | -11.326 | -27.574 | -4.320 | -1.829 | |
| Debt To Assets Ratio | 0.028 | 0.072 | 0.117 | 0.257 | 0.145 | |
| Debt To Equity Ratio | 0.034 | 0.121 | 0.810 | -0.834 | 0.921 | |
| Debt To Capital Ratio | 0.033 | 0.108 | 0.448 | -5.031 | 0.479 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.213 | 1.681 | 6.938 | -3.246 | 6.370 | |
| Working Capital Turnover Ratio | 0.117 | 0.838 | 2.984 | 0.058 | 0.395 | |
| Operating Cash Flow Ratio | -1.972 | -1.361 | -0.104 | -1.787 | -1.386 | |
| Operating Cash Flow Sales Ratio | -4.388 | -1.394 | -0.171 | -35.018 | -2.172 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.006 | 1.057 | 1.011 | 1.006 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -10.553 | -5.945 | -0.605 | -3.397 | -2.975 | |
| Capital Expenditure Coverage Ratio | -261.132 | -161.009 | -17.427 | -93.888 | -158.916 | |
| Dividend Paid And Capex Coverage Ratio | -261.132 | -161.009 | -17.427 | -93.888 | -158.916 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -11.675 | -16.230 | -7.504 | -3.318 | -0.374 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 79.3% | ▼-20.7% | ▼-16.6% |
| Ebit Margin | -478.3% | ▼-388.8% | ▲588.5% |
| Ebitda Margin | -457.6% | ▼-376.0% | ▲541.6% |
| Operating Profit Margin | -504.1% | ▼-402.1% | ▲583.0% |
| Pretax Profit Margin | -478.3% | ▼-388.8% | ▲588.5% |
| Continuous Operations Profit Margin | -478.3% | ▼-388.8% | ▲592.0% |
| Net Profit Margin | -478.3% | ▼-388.8% | ▲592.0% |
| Bottom Line Profit Margin | -478.3% | ▼-388.8% | ▲592.0% |
| Current Ratio | 6.467 | ▲3.580 | ▲3.562 |
| Quick Ratio | 6.467 | ▲3.580 | ▲3.562 |
| Solvency Ratio | -1.742 | ▼-1.123 | ▼-0.941 |
| Cash Ratio | 6.333 | ▲3.611 | ▲3.591 |
| Price To Earnings Ratio | -14.050 | ▲3.622 | ▼-4.886 |
| Price To Earnings Growth Ratio | -0.193 | ▲0.404 | ▼-0.119 |
| Forward Price To Earnings Growth Ratio | -0.193 | ▲0.404 | ▼-0.119 |
| Price To Earnings Diluted Ratio | -14.050 | ▲3.622 | ▼-4.886 |
| Price To Earnings Diluted Growth Ratio | -0.193 | ▲0.404 | ▼-0.119 |
| Price To Book Ratio | 5.448 | ▼-2.716 | ▲1.469 |
| Price To Sales Ratio | 67.102 | ▲51.308 | ▲18.528 |
| Price To Free Cash Flow Ratio | -15.291 | ▼-4.036 | ▼-3.548 |
| Price To Operating Cash Flow Ratio | -15.291 | ▼-3.966 | ▼-3.224 |
| Debt To Assets Ratio | 0.028 | ▼-0.044 | ▼-0.096 |
| Debt To Equity Ratio | 0.034 | ▼-0.087 | ▼-0.177 |
| Debt To Capital Ratio | 0.033 | ▼-0.075 | ▲0.825 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.213 | ▼-0.468 | ▼-1.378 |
| Working Capital Turnover Ratio | 0.117 | ▼-0.721 | ▼-0.761 |
| Operating Cash Flow Ratio | -1.972 | ▼-0.611 | ▼-0.650 |
| Operating Cash Flow Sales Ratio | -4.388 | ▼-2.994 | ▲4.241 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.006 | ▼-0.016 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -10.553 | ▼-4.609 | ▼-5.858 |
| Capital Expenditure Coverage Ratio | -261.132 | ▼-100.124 | ▼-122.658 |
| Dividend Paid And Capex Coverage Ratio | -261.132 | ▼-100.124 | ▼-122.658 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -11.675 | ▲4.555 | ▼-3.855 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.87B | $1.71B | $535.8M | $552.0M | $162.7M | |
| Enterprise value | $2.28B | $1.43B | $367.6M | $501.1M | $42.1M | |
| EV / Sales | 53.43x | 13.24x | 3.24x | 137.33x | 1.03x | |
| EV / Op. cash flow | -12.18x | -9.49x | -18.92x | -3.92x | -0.47x | |
| EV / Free cash flow | -12.18x | -9.44x | -17.89x | -3.88x | -0.47x | |
| EV / EBITDA | -11.68x | -16.23x | -7.50x | -3.32x | -0.37x | |
| Net debt / EBITDA | 2.99x | 3.13x | 3.43x | 0.34x | 1.07x | |
| Current ratio | 6.47x | 2.89x | 1.26x | 1.38x | 2.53x | |
| Income quality | 0.92x | 1.56x | 0.34x | 0.79x | 0.73x | |
| Graham net-net | $3 | $1 | -$0 | -$1 | -$0 | |
| Tax burden | 100.0% | 100.0% | 98.8% | 100.4% | 99.8% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $519.7M | $209.4M | $48.9M | $27.0M | $98.4M | |
| Invested capital | $539.6M | $237.4M | $84.7M | $71.1M | $139.0M | |
| Return on assets | -32.0% | -27.5% | -20.9% | -110.5% | -59.1% | |
| Operating ROA | -43.5% | -35.2% | -32.3% | -92.1% | -52.2% | |
| Return on tangible assets | -32.0% | -27.5% | -20.9% | -110.5% | -59.1% | |
| Return on equity | -38.8% | -46.3% | -145.1% | 358.9% | -376.2% | |
| Return on invested capital | -39.0% | -44.4% | -70.6% | -202.5% | -85.8% | |
| Return on capital employed | -39.6% | -45.8% | -76.8% | -217.4% | -88.9% | |
| Earnings yield | -7.1% | -5.7% | -10.7% | -29.3% | -75.1% | |
| Free cash flow yield | -6.5% | -8.9% | -3.8% | -23.4% | -55.0% | |
| Capex / Op. cash flow | -0.4% | -0.6% | -5.7% | -1.1% | -0.6% | |
| Capex / Depreciation | 8.1% | 10.8% | 12.1% | 13.5% | 5.7% | |
| Capex / Sales | 1.7% | 0.9% | 1.0% | 37.3% | 1.4% | |
| SG&A / Sales | 176.3% | 54.5% | 45.3% | 1384.3% | 112.6% | |
| R&D / Sales | 427.8% | 147.4% | 114.7% | 3175.0% | 297.5% | |
| Stock comp / Sales | 0.0% | 12.1% | 8.6% | 471.2% | 40.1% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 11d | 5d | 68d | 0d | 0d | |
| Days payables outstanding | 647d | 0d | 0d | 0d | 0d | |
| Operating cycle | 11d | 5d | 68d | 0d | 0d | |
| Cash conversion cycle | -636d | 5d | 68d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+67.6%EV / Sales ▲+303.5%EV / EBITDA ▲+28.1%EV / Op. cash flow ▼-2.681Earnings yield ▼-0.015
Profitability
Return on equity ▲+0.075Return on assets ▼-0.045Return on invested capital ▲+0.053Return on capital employed ▲+0.061Operating ROA ▼-0.083Income quality ▼-0.639Tax burden 0.000
Efficiency
Days sales outstanding ▲+6.108Days payables outstanding n/aOperating cycle ▲+6.108Cash conversion cycle ▼-641.260Capex / Sales ▲+0.008R&D / Sales ▲+2.803
Balance-sheet strength
Current ratio ▲+3.580Net debt / EBITDA ▼-0.143Working capital ▲+310308000.000Invested capital ▲+302173000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+1661.8%EV / Sales ▲+5100.4%EV / EBITDA ▼-3024.1%EV / Op. cash flow ▼-11.702Earnings yield ▲+0.680
Profitability
Return on equity ▲+3.373Return on assets ▲+0.270Return on invested capital ▲+0.468Return on capital employed ▲+0.493Operating ROA ▲+0.088Income quality ▲+0.189Tax burden ▲+0.002
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales ▲+0.003R&D / Sales ▲+1.303
Balance-sheet strength
Current ratio ▲+3.935Net debt / EBITDA ▲+1.917Working capital ▲+421386000.000Invested capital ▲+400605000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-13 Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover Wave Life Sciences (NASDAQ:WVE) trades at $5.24, a step above its 52-week low of $5.01 and far beneath the 52-week high of $21.73.
- 2026-08-11 Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
- 2026-08-10 Wave Life Sciences Announces Completion of Redomiciliation to Delaware CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), today announced the completion of the redomiciliation process to change the parent company of the Wave group of companies from a Singapore company to a Delaware corporation by way of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Redomiciliation”).
- 2026-08-05 Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd.
- 2026-08-04 Wave Life Sciences to Present at Upcoming Investor Conferences CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave''s management team are scheduled to participate in two upcoming investor conferences in August.
- 2026-07-30 WAVE Life Sciences Q2 Earnings Call Highlights WAVE Life Sciences NASDAQ: WVE reported a wider second-quarter loss as it increased investment in its obesity and RNA-editing programs, while outlining several clinical and regulatory milestones expected in the second half of 2026.
- 2026-07-30 Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript
- 2026-07-30 Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates Wave Life Sciences (WVE) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.31 per share a year ago.
- 2026-07-30 Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; trial will also inform WVE-007''s potential in MASH, type 2 diabetes, and other cardiometabolic diseases
- 2026-07-23 Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026 CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, July 30, 2026, to review the company''s second quarter 2026 financial results and provide business updates.